Form 4: Sage Therapeutics Director Elizabeth Barrett Granted Stock Options Under 2024 Equity Incentive Plan

Sage Therapeutics, Inc. director Elizabeth Barrett was granted 21,500 stock options with an exercise price of $6.77, vesting fully by June 2026, as part of the company's non-employee director compensation program.

Summary

• Elizabeth A. Barrett, a Director of Sage Therapeutics, Inc. (SAGE), was granted 21,500 stock options.
• The options have an exercise price of $6.77 per share.
• The grant date for these options was June 11, 2025.
• The options will expire on June 11, 2035.
• This award was issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.
• It is in accordance with Sage's Non-Employee Director Compensation Program.
• The options will vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, contingent on continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation disclosure, which is positive for the recipient and indicates standard corporate governance practices. There are no negative financial implications immediately, though potential future dilution is a minor consideration.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The award is part of a pre-existing, disclosed compensation program (Non-Employee Director Compensation Program) and an approved equity incentive plan (2024 Equity Incentive Plan), indicating structured governance.

Negatives

• The issuance of stock options can lead to potential future dilution for existing shareholders if exercised.

Risks

• Future dilution risk if the stock options are exercised, increasing the number of outstanding shares.
• The value of the options is dependent on the future stock price of Sage Therapeutics, Inc., which is subject to market fluctuations and company performance.

Future Outlook

The stock options granted to Director Elizabeth Barrett are set to vest in full by June 11, 2026, or earlier, contingent on her continued service as a director until the day prior to the 2026 Annual Meeting of Stockholders. The options have an expiration date of June 11, 2035, providing a long-term incentive.

Management Comments

• The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program.

Industry Context

This filing is a routine disclosure of director compensation in the form of stock options, a common practice across industries, including biotechnology and pharmaceuticals, to align the interests of non-employee directors with shareholders and incentivize long-term value creation. Such grants are standard components of executive and director compensation packages.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which often use equity awards to attract and retain qualified board members.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity awards, ensuring commitment over a defined period.
• The exercise price being the market price on the grant date ($6.77) is also a common structure for incentive stock options or non-qualified stock options granted to directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Elizabeth Barrett, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from incentivized director performance.
• Elizabeth Barrett (Director): Receives equity compensation, aligning her financial interests with the company's long-term success.
• Employees: No direct impact mentioned, but the 2024 Equity Incentive Plan could also apply to employees.

Next Steps

• Elizabeth Barrett's continued service as a director of Sage Therapeutics, Inc.
• Vesting of the 21,500 stock options by June 11, 2026, or prior to the 2026 Annual Meeting of Stockholders.
• Potential future exercise of the stock options by Elizabeth Barrett before the June 11, 2035 expiration date.

Key Dates

Keywords

Sage Therapeutics, SAGE, SEC Form 4, Stock Options, Equity Incentive Plan, Director Compensation, Beneficial Ownership, Insider Transaction, Corporate Governance, Biotechnology, Pharmaceuticals